{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T05:47:55Z","timestamp":1785044875258,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Daiichi Sankyo, Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Patients with atrial fibrillation (AF) and a recent (\u2264\u200990\u00a0days) percutaneous coronary intervention (PCI) undergoing transcatheter aortic valve implantation (TAVI) are at high bleeding risk due to the addition of oral antiplatelet (OAP) agents on top of oral anticoagulants. Data on outcomes of these patients are needed to optimize antithrombotic treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This analysis compared annualized clinical event rates in patients with and without a recent PCI enrolled in ENVISAGE-TAVI AF, a prospective, randomized, open-label, adjudicator-masked trial comparing edoxaban and vitamin K antagonists in AF patients after TAVI. The primary efficacy and safety outcomes were net adverse clinical events (NACE) and major bleeding.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Overall, 132 (94.3%) patients with a recent PCI (<jats:italic>n<\/jats:italic>\u2009=\u2009140) received OAP after TAVI, compared with 692 (55.9%) patients without a recent PCI (<jats:italic>n<\/jats:italic>\u2009=\u20091237). Among patients with a recent PCI on OAP agents, use of dual antiplatelet therapy decreased to 5.5%, and use of single antiplatelet therapy (SAPT) increased to 78.0% over 3\u00a0months post-randomization. Conversely, use of SAPT predominated at all time points in patients without a recent PCI history. There were no significant differences in the incidence of NACE or other outcomes assessed, except for major bleeding events, which were more frequent in patients with vs without a recent PCI history (hazard ratio [95% confidence interval]: 2.17 [1.27, 3.73]; <jats:italic>P<\/jats:italic>\u2009=\u20090.005).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Patients with AF undergoing TAVI with a recent PCI have a similar risk of ischemic events and mortality, but an increased risk of major bleeding compared with patients without a recent PCI.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1007\/s00392-024-02379-5","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T12:02:44Z","timestamp":1706702564000},"page":"313-322","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Outcomes after TAVI in patients with atrial fibrillation and a history of recent PCI: Results from the ENVISAGE-TAVI AF trial"],"prefix":"10.1007","volume":"114","author":[{"given":"Ra\u00fal","family":"Moreno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Smolnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Nombela-Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas M.","family":"Van Mieghem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hengstenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Ohlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Dangas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Unverdorben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helge","family":"M\u00f6llmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"issue":"3","key":"2379_CR1","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jacc.2019.06.012","volume":"74","author":"L Faroux","year":"2019","unstructured":"Faroux L, Guimaraes L, Wintzer-Wehekind J et al (2019) Coronary artery disease and transcatheter aortic valve replacement: JACC state-of-the-art review. J Am Coll Cardiol 74(3):362\u2013372","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"2379_CR2","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1056\/NEJMoa1816885","volume":"380","author":"JJ Popma","year":"2019","unstructured":"Popma JJ, Deeb GM, Yakubov SJ et al (2019) Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 380(18):1706\u20131715","journal-title":"N Engl J Med"},{"issue":"23","key":"2379_CR3","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa1103510","volume":"364","author":"CR Smith","year":"2011","unstructured":"Smith CR, Leon MB, Mack MJ et al (2011) Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 364(23):2187\u20132198","journal-title":"N Engl J Med"},{"issue":"18","key":"2379_CR4","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.jcin.2021.06.041","volume":"14","author":"T Patterson","year":"2021","unstructured":"Patterson T, Clayton T, Dodd M et al (2021) ACTIVATION (PercutAneous coronary inTervention prIor to transcatheter aortic VAlve implantaTION): A randomized clinical trial. JACC Cardiovasc Interv 14(18):1965\u20131974","journal-title":"JACC Cardiovasc Interv"},{"issue":"6","key":"2379_CR5","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.recesp.2021.11.023","volume":"75","author":"A Vahanian","year":"2022","unstructured":"Vahanian A, Beyersdorf F, Praz F et al (2022) 2021 ESC\/EACTS guidelines for the management of valvular heart disease: Developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Rev Esp Cardiol (Engl Ed) 75(6):524","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"2","key":"2379_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","volume":"40","author":"FJ Neumann","year":"2019","unstructured":"Neumann FJ, Sousa-Uva M, Ahlsson A et al (2019) 2018 ESC\/EACTS guidelines on myocardial revascularization. Eur Heart J 40(2):87\u2013165","journal-title":"Eur Heart J"},{"issue":"11","key":"2379_CR7","doi-asserted-by":"publisher","first-page":"e004395","DOI":"10.1161\/CIRCINTERVENTIONS.116.004395","volume":"9","author":"DJ Angiolillo","year":"2016","unstructured":"Angiolillo DJ, Goodman SG, Bhatt DL et al (2016) Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: A North American perspective-2016 update. Circ Cardiovasc Interv 9(11):e004395","journal-title":"Circ Cardiovasc Interv"},{"issue":"23","key":"2379_CR8","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1093\/eurheartj\/ehab196","volume":"42","author":"J Ten Berg","year":"2021","unstructured":"Ten Berg J, Sibbing D, Rocca B et al (2021) Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: A consensus document of the ESC working group on thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on valvular heart disease. Eur Heart J 42(23):2265\u20132269","journal-title":"Eur Heart J"},{"key":"2379_CR9","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","volume":"385","author":"NM Van Mieghem","year":"2021","unstructured":"Van Mieghem NM, Unverdorben M, Hengstenberg C et al (2021) Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med 385:2150\u20132610","journal-title":"N Engl J Med"},{"issue":"22","key":"2379_CR10","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMra1206531","volume":"368","author":"TH Baron","year":"2013","unstructured":"Baron TH, Kamath PS, McBane RD (2013) Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med 368(22):2113\u20132124","journal-title":"N Engl J Med"},{"issue":"5","key":"2379_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N et al (2021) 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC. Eur Heart J 42(5):373\u2013498","journal-title":"Eur Heart J"},{"key":"2379_CR12","doi-asserted-by":"crossref","unstructured":"January CT, Wann LS, Calkins H et al (2019) AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol 74(1):104\u2013132","DOI":"10.1161\/CIR.0000000000000665"},{"issue":"4","key":"2379_CR13","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692\u2013694","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2379_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1161\/CIRCINTERVENTIONS.112.000124","volume":"6","author":"S Stortecky","year":"2013","unstructured":"Stortecky S, Buellesfeld L, Wenaweser P et al (2013) Atrial fibrillation and aortic stenosis: Impact on clinical outcomes among patients undergoing transcatheter aortic valve implantation. Circ Cardiovasc Interv 6(1):77\u201384","journal-title":"Circ Cardiovasc Interv"},{"issue":"12","key":"2379_CR15","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.3390\/jcm9123987","volume":"9","author":"D Morrone","year":"2020","unstructured":"Morrone D, Kroep S, Ricci F et al (2020) Mortality prediction of the CHA(2)DS(2)-VASc score, the HAS-BLED score, and their combination in anticoagulated patients with atrial fibrillation. J Clin Med 9(12):3987","journal-title":"J Clin Med"},{"issue":"9","key":"2379_CR16","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/j.amjcard.2017.07.051","volume":"120","author":"X Yao","year":"2017","unstructured":"Yao X, Gersh BJ, Sangaralingham LR et al (2017) Comparison of the CHA(2)DS(2)-VASc, CHADS(2), HAS-BLED, ORBIT, and ATRIA risk scores in predicting non-vitamin K antagonist oral anticoagulants-associated bleeding in patients with atrial fibrillation. Am J Cardiol 120(9):1549\u20131556","journal-title":"Am J Cardiol"},{"issue":"18","key":"2379_CR17","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa1915152","volume":"382","author":"VJ Nijenhuis","year":"2020","unstructured":"Nijenhuis VJ, Brouwer J, Delewi R et al (2020) Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med 382(18):1696\u20131707","journal-title":"N Engl J Med"},{"issue":"4","key":"2379_CR18","doi-asserted-by":"publisher","first-page":"e009963","DOI":"10.1161\/CIRCINTERVENTIONS.120.009963","volume":"14","author":"MW Sherwood","year":"2021","unstructured":"Sherwood MW, Gupta A, Vemulapalli S et al (2021) Variation in antithrombotic therapy and clinical outcomes in patients with preexisting atrial fibrillation undergoing transcatheter aortic valve replacement: Insights from the Society of Thoracic Surgeons\/American College of Cardiology Transcatheter Valve Therapy Registry. Circ Cardiovasc Interv 14(4):e009963","journal-title":"Circ Cardiovasc Interv"},{"issue":"41","key":"2379_CR19","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","volume":"38","author":"T Cuisset","year":"2017","unstructured":"Cuisset T, Deharo P, Quilici J et al (2017) Benefit of switching dual antiplatelet therapy after acute coronary syndrome: The TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J 38(41):3070\u20133078","journal-title":"Eur Heart J"},{"issue":"10257","key":"2379_CR20","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0140-6736(20)31791-8","volume":"396","author":"HS Kim","year":"2020","unstructured":"Kim HS, Kang J, Hwang D et al (2020) Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): An open-label, multicentre, non-inferiority randomised trial. Lancet 396(10257):1079\u20131089","journal-title":"Lancet"},{"issue":"10194","key":"2379_CR21","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(19)31126-2","volume":"394","author":"TT Rissanen","year":"2019","unstructured":"Rissanen TT, Uskela S, Eranen J et al (2019) Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): A single-blind, randomised, non-inferiority trial. Lancet 394(10194):230\u2013239","journal-title":"Lancet"},{"issue":"21","key":"2379_CR22","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","volume":"373","author":"P Urban","year":"2015","unstructured":"Urban P, Meredith IT, Abizaid A et al (2015) Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med 373(21):2038\u20132047","journal-title":"N Engl J Med"},{"issue":"13","key":"2379_CR23","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1056\/NEJMoa1910021","volume":"382","author":"S Windecker","year":"2020","unstructured":"Windecker S, Latib A, Kedhi E et al (2020) Polymer-based or polymer-free stents in patients at high bleeding risk. N Engl J Med 382(13):1208\u20131218","journal-title":"N Engl J Med"},{"issue":"10206","key":"2379_CR24","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","volume":"394","author":"P Vranckx","year":"2019","unstructured":"Vranckx P, Valgimigli M, Eckardt L et al (2019) Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): A randomised, open-label, phase 3b trial. Lancet 394(10206):1335\u20131343","journal-title":"Lancet"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-024-02379-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-024-02379-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-024-02379-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T08:55:05Z","timestamp":1742201705000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-024-02379-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2379"],"URL":"https:\/\/doi.org\/10.1007\/s00392-024-02379-5","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,31]]},"assertion":[{"value":"25 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ENVISAGE-TAVI AF protocol was approved by the ethics committees and corresponding health authorities for all sites. All patients provided written informed consent before enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statements"}},{"value":"RM received payments for personal fees from Abbott Vascular, AMGEN, Biosensors, Boston Scientific, Daiichi Sankyo, Edwards Lifesciences, Ferrer, Medtronic, Philips, and Terumo; LNF is a proctor for Abbott Medical and received personal fees from Abbott Medical, Boston Scientific, and Edwards Lifesciences; NVM received grants or contracts from Abbott, Abiomed, Boston Scientific, Daiichi Sankyo, Edwards Lifesciences, Medtronic, PulseCath BV, and Siemens; CH is a clinical proctor for Edwards Lifesciences and Boston Scientific; received research grants to institution from Abbott, Boston Scientific, Edwards Lifesciences, and Medtronic; and reports payment for speaker bureaus and support for attending meetings from Daiichi Sankyo and advisory board participation for Daiichi Sankyo; MV received grants and personal fees from Terumo and has received personal fees from AstraZeneca, Alvimedica\/CID, Abbott Vascular, Daiichi Sankyo, Bayer, CoreFlow, Idorsia Pharmaceuticals LTD, Universit\u00e4t Basel, Dept. Klinische Forschung, Vifor, Bristol Myers Squibb SA, Biotronik, Boston Scientific, Medtronic, Vesalio, Novartis, Chiesi, and PhaseBio; PO has nothing to disclose; HM received personal fees from Daiichi Sankyo, Pfizer, Bristol Myers Squibb, Boehringer Ingelheim, Edwards Lifesciences, Boston Scientific, Abbott Medical, and AstraZeneca and support for attending meetings from Daiichi Sankyo, Pfizer, Edwards Lifesciences, Boston Scientific, Abbott Medical, and AstraZeneca; GD received research grants to institution and support for attending meetings from Bayer and Daiichi Sankyo and consulting fees from Daiichi Sankyo; and JS, RS, JJ, and MU are employees of Daiichi Sankyo.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}